Mace Construct appoints interim director


Mace Construct has appointed an interim public sector and life sciences lead. 

Rob Lemming. Credit: Mace.

As the new interim managing director of the business, Rob Lemming will temporarily oversee work winning and project delivery, while supporting Mace Construct’s growth targets. 

After more than 10 years at Mace, Lemming has played a crucial role in the delivery of key projects, including the Discovery Centre for AstraZeneca in Cambridge, while helping to grow its presence in the life sciences sector across London, Oxford and Cambridge. 

Prior to joining Mace, Lemming worked at Skanska for more than 11 years where he held project manager and construction manager roles in the healthcare division.  

He succeeds Terry Spraggett who stepped down from his position in December after 18 years with the company. 

Mace will run a recruitment process over the coming months for the permanent job.  

He said: “I am thrilled to be taking the reins of our Public Sector and Life Sciences business unit at such a significant time for these crucial sectors. 

“When it comes to life sciences, this is one the UK’s biggest growth sectors with an ever-growing demand for quality lab space. We are working with a number of clients across the golden triangle to build state-of-the-art research spaces enabling scientific research and discovery.” 

Gareth Lewis, chief executive, Mace Construct, said: “Rob has been absolutely dedicated to growing Mace’s capability in the life sciences sector over the last decade, and I’m pleased he is taking on this interim role as we look for a permanent placement. 

“Rob’s experience and knowledge of the industry will ensure continuity and consistency for all of our clients working on the iconic projects we are lucky to be building across the capital and beyond.” 

Was this interesting? Try Glencar targets 20% revenue growth in 2024         

If you have a tip or story idea that fits with our publication, please contact the news editor rory@wavenews.co.uk 

Get industry news in 5 minutes!

A daily email that makes industry news enjoyable. It’s completely free.